Spain · Delayed Price · Currency is EUR Oryzon Genomics Company Description
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders.
Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases.
Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others.
It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials.
The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
| Country | Spain |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Carlos Manuel Arjol |
Contact Details
Address: Sant Ferran 74 Cornellà de Llobregat, 08940 Spain | |
| Phone | 34 93 515 13 13 |
| Website | oryzon.com |
Stock Details
| Ticker Symbol | ORY |
| Exchange | Madrid Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | ES0167733015 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carlos Manuel Buesa Arjol | Co-Founder, Chairman, Chief Executive Officer and President |
| Enric Rello Condomines | Chief Operating Officer and Chief Financial Officer |
| Jordi Xaus Pey | Scientific Director |
| Xavier Perpinya Ribera | Head of Internal Audit and Compliance |
| Dr. Rolando Gutierrez-Esteinou M.D. | Chief Medical Officer for CNS Programs |
| Augusto Pinel Rubio | Secretary |
| Emili Torrell Cortada | Director of Business Development |
| Neus Virgili Bernado | Director of Industrial Property |
| Sonia Paloma Gutierrez Bezon | Director of Clinical Operations |